Has Yehuda Handelsman received payments from drug or device companies?

Yes. Drug and device makers reported $1,417,193 in general payments to Yehuda Handelsman across 1,132 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yehuda Handelsman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yehuda Handelsman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yehuda Handelsman

Endocrinology, Diabetes & Metabolism · Tarzana, CANPI 1063453769

Payments from drug & device makers

$1,417,193in general payments, 2019–2025

Across 1,132 payments — averaging $1251.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$307K
Regeneron$199K
Sanofi-aventis U.S. LLC$163K
Amgen$162K
AstraZeneca$126K
Novo Nordisk AS$57K
plus $403K from 48 others

$2,212in research payments, 2019–2025

Across 11 payments — averaging $201.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$2K
Amgen$652

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	276	$306,956
Regeneron	101	$198,574
Sanofi-aventis U.S. LLC	57	$163,135
Amgen(2 entities)	80	$162,452
AstraZeneca(2 entities)	117	$125,824
Novo Nordisk AS	47	$56,942
Boehringer Ingelheim	47	$56,869
Esperion Therapeutics, Inc.	50	$47,655
Applied Therapeutics, Inc.	14	$42,351
Corcept Therapeutics	37	$39,782
Sanofi US Services Inc.	14	$34,637
Astrazeneca UK Limited	10	$33,726
Merck	46	$32,430
Amarin Pharma, Inc.	29	$23,369
Johnson & Johnson	25	$13,114
Eli Lilly	2	$9,681
Vistapharm, Inc.	6	$8,700
Boehringer Ingelheim International GmbH	4	$8,217
Azurity Pharmaceuticals, Inc.	8	$7,448
Ionis Pharmaceuticals, Inc.	3	$7,419
Janssen Scientific Affairs, LLC	8	$7,339
Lilly USA, LLC	21	$6,138
Sanofi	1	$5,733
E.r. Squibb & Sons, L.L.C.	1	$4,207
Bayer	9	$4,051
Novartis	19	$3,858
Mannkind Corporation	17	$3,450
Abbott	16	$779
Lexicon Pharmaceuticals, Inc.	5	$331
AbbVie	14	$328
Insulet Corporation	4	$259
Cleerly, Inc.	1	$156
Cequr Corporation	2	$153
Regeneron Healthcare Solutions, Inc.	2	$137
Intuitive Surgical	1	$115
GSK	2	$99
Madrigal Pharmaceuticals	4	$96
Ascendis Pharma Endocrinology Inc	3	$76
Dexcom, Inc.	4	$72
Kyowa Kirin, Inc.	3	$68
GRT US Holding, Inc.	2	$60
BETA Bionics, Inc.	2	$58
Xeris Pharmaceuticals, Inc.	3	$49
Recordati_rare_diseases_inc.	2	$48
IBSA Pharma Inc.	2	$48
Janssen Global Services, LLC	1	$41
Medtronic	1	$31
Tolmar, Inc.	1	$28
Sequel Med Tech, LLC	1	$25
Chiesi USA, Inc.	1	$23
Ultragenyx Pharmaceutical Inc.	1	$22
Acorda Therapeutics, Inc	1	$19
Zealand Pharma US, Inc.	1	$14
Travere Therapeutics, Inc.	3	$2

How this compares

$1,417,193 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Other endocrinology, diabetes & metabolism in Tarzana

Jerrold OlefskySan Diego$26.5M
Mark ChristiansenWalnut Creek$22.9M
Timothy BaileyEscondido$22.3M
Stanley HsiaLos Angeles$19.8M
Juan FriasSan Diego$14.1M
Paul NorwoodFresno$6.2M
Athena Philis-Tsimikasla Jolla$6M
David AhnNewport Beach$5.8M
Shlomo MelmedLos Angeles$3.3M
Leila ChaychiSan Carlos$3.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →